12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] Technology appraisal guidance Abatacept for treating active ...

NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

A list of downloadable documents created during development.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Erdafitinib (Balversa) is available on the NHS. It is a possible treatment for urothelial cancer in adults when the cancer: is unresectable (cannot be surgically removed) or metastatic (has spread to ...

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...